| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Emergent Biosolutions Inc. (EBS) has 13 insiders with recent SEC Form 4 filings, including 0 buys and 18 sells. EBS is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 305.4K | $2.54M | - | |
| CFO | 215.4K | $1.79M | - | |
| Dir | 119.9K | $998.4K | - | |
| VP | 104.1K | $867.2K | - | |
| Dir | 89.0K | $741.2K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 7, 2019 | Richard Ronald | Director | Sale+OE | 5,153 | $60.00 | $309,180.00 | -16.2% | |
| Sep 9, 2019 | Zoon Kathryn C62 | Director | Sell | 1,509 | $56.12 | $84,692.02 | -6.6% | |
| May 28, 2019 | Zoon Kathryn C62 | Director | Sell | 1,376 | $43.39 | $59,702.44 | -5.6% | |
| Mar 11, 2019 | Havey Adam | EVP, Business Operations | Sell | 2,430 | $56.93 | $138,339.90 | -7.0% | |
| Mar 4, 2019 | Abdun-Nabi Daniel | CEO | Sell | 14,565 | $58.11 | $846,328.46 | -9.3% | |
| Mar 1, 2019 | Havey Adam | EVP, Business Operations | Sell | 3,043 | $58.11 | $176,819.11 | -4.1% | |
| Feb 28, 2019 | El-Hibri Fuad | Chairman | Sale+OE | 27,725 | $58.83 | $1,630,931.30 | -0.6% | |
| Nov 27, 2018 | Bailey Sue | Director | Sale+OE | 17,717 | $69.62 | $1,233,452.22 | -8.3% | |
| Nov 27, 2018 | El-Hibri Fuad | Chairman | Sell | 45,832 | $69.79 | $3,198,698.88 | -1.6% | |
| Nov 20, 2018 | El-Hibri Fuad | Chairman | Sell | 35,173 | $69.75 | $2,453,365.19 | -1.2% |